Top Rated Speakers Include:

Achieving Commercial Success through the Implementation of Amorphous Techniques

Amorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development, partly due to the increasing proportion of insoluble drug molecules in development. Owing to the lack of an ordered crystal lattice, amorphous forms require minimal energy and therefore offer enhanced solubility, dissolution rate, and bioavailability - properties which are all integral to the effectiveness and success of future medicines.

Currently, several amorphous drugs have made it to market, but in many cases stabilising amorphous systems while maintaining these physico-chemical advantages still remains a major challenge in the pharmaceutical arena.

For that reason, Amorphous Pharmaceutical Materials 2010 will explore the results and knowledge acquired over the years on perfecting the art of amorphous formation and stabilisation. This will thus ensure consistency of amorphous drugs from the laboratory to manufacture, with the ultimate aim of realising the commercial potential of amorphous forms in pharmaceutical drugs.


Pharmaceutical-Co-Crystals-2010

Topics from leading pharmaceutical and academic professionals in the field will include:

  • Assess the importance of the amorphous drug phase, drug-polymer cast films and down-scaled processing techniques in the success of an amorphous solid dispersion and analyse marketed case studies, Sporanox® and Intelence® with Dr Marcus Brewster, Johnson & Johnson
  • Understand Crystal Defects as Pathways Towards Disorder and gain insights into how computer modelling of defect pathways can be used to understand disorder within your drug candidates with Dr Brian Luisi, Vertex Pharmaceuticals
  • Explore the basic operating principles of hot-melt extrusion, KinetiSol® dispersing and thermally processed amorphous systems and hear examples of successful employment of supersaturating drug delivery systems by thermal processing techniques from Dr Dave Miller, Hoffmann La Roche
  • Analyse the methods for solid dispersion screening with limited material supply, including lyophilisation and evaluate crystallisation inhibition potential of excipients; insights from Dr Joseph Lubach, Genentech
  • Advance the amorphous pipeline by: achieving rapid screening of excipients for early-stage amorphous solid dispersions, in-vitro testing of early-stage amorphous solid dispersions to measure supersaturation, etc and addressing scale-up issues for early-stage amorphous solid dispersions - approaches from Dr Brian Padden, Abbott Laboratories
  • Investigate the interplay of kinetics and thermodynamics in forming amorphous solid dispersions and capture the benefits of superior kinetic solubility and apply thermodynamic principles to metastable systems to achieve amorphous stability and, in turn, enhance solid dispersion formation and performance: methods from Dr Patrick Marsac, Senior Research Pharmacist, Merck

To see more details about these talks and the rest of the outstanding sessions simply download the brochure

Testimonials

Again, good overview of recent developments
Marco Gil, Hovione Farmaciencia SA
This was an excellent opportunity to get an overall picture of the field.
Adam Demeter, Gedeon Richter Plc
Very good, very high level in every direction, skills of presentation, content of presentation, slides. Highly valuable on the learning about amorphous practical cases & theoretical approach.
Dr Daniele Schott, Solvias AG
Excellent talks. All presentations were interesting, detailed & well explained. Extremely valuable-I've learned a lot about amorphous characterisation, generation & control.
Caitriona Cashell, GlaxoSmithKline


Session Sponsor Featured exhibitor
veeco kuecept
Media Partners
Media-Partners

[ Register Now ]